Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review

Table 4 Comparison of the hepatic efficacy (continuous) outcomes in the efruxifermin vs placebo arms

Outcome variables (continuous)	EFX dose (mg)	No. of study reports	No. of participants with outcome analyzed		Pooled effect size, MD (95%CI)	P value (EFX vs placebo)	I2 (%)	P value (EFX 28 vs 50)
			EFX arm	Placebo arm
HFF (relative change) (%)	28	2	57	63	-54.06 (-71.01 to -37.11)	< 0.00001	76	0.42
	50	3	71	73	-62.00 (-71.27 to -52.73)	< 0.00001	31
HFF (absolute change) (%)	50	2	36	31	-9.30 (-16.36 to -2.23)	0.01	87	NA
ELF score	28	3	113	124	-0.67 (-0.83 to -0.51)	< 0.00001	0	0.46
	50	5	166	144	-0.75 (-0.89 to -0.61)	< 0.00001	0
Liver stiffness (kPa)	28	2	95	103	-1.90 (-3.88 to 0.08)	0.06	0	0.92
	50	4	138	123	-2.00 (-2.51 to -1.50)	< 0.00001	0
Pro-C3 (μg/L)	28	3	113	122	-5.42 (-8.15 to -2.70)	< 0.00001	68	0.69
	50	5	157	142	-6.11 (-8.06 to -4.16)	< 0.00001	53
Pro-C3 (%)	50	2	83	71	-20.85 (-36.07 to -5.64)	0.007	0	NA

EFX: Efruxifermin; ELF: Enhanced liver fibrosis; HFF: Hepatic fat fraction; kPa: Kilopascals; MD: Mean difference; NA: Not available; Pro-C3: N-terminal propeptide of type III collagen.